who benefits from immunotherapy in patients with advanced escc?
Published 1 year ago • 120 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:44
chemo-immunotherapy in patients with locally advanced gastroesophageal cancer
-
2:42
the benefits of immunotherapy versus chemotherapy: analyzing the results of the ipsos trial
-
1:27
which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?
-
1:19
29-month follow-up from checkmate 648: nivolumab combination therapy in escc
-
3:34
role of immunotherapy in the management of mesothelioma
-
2:01
highlights from sitc 2021 on immunotherapy in solid tumors
-
4:03
rationale-306: tislelizumab and chemotherapy in escc
-
0:54
neon-1 & neon-2: alpn-202 alone or with pembrolizumab in patients with advanced malignancies
-
18:41
who benefits from immunotherapy?
-
1:54
balancing the benefits and costs of immunotherapy in the treatment of lung cancer
-
2:50
immunotherapy updates from wclc 2021
-
4:59
checkmate 648: 1l io-io in advanced esophageal squamous cell carcinoma
-
4:01
the role of immunotherapy in gastrointestinal cancers: an update from esmo
-
1:01
long-term efficacy of nivolumab combinations in advanced escc in checkmate 648
-
2:32
current status of immunotherapy for advanced melanoma
-
2:25
efficacy of pembrolizumab treatment in mucosal melanoma
-
4:23
keynote-407: 3-year follow-up of pembrolizumab plus chemo in nsclc
-
0:45
how to discuss immunotherapy as a treatment option with lung cancer patients
-
1:02
long-term benefits of the dcf regimen in the jcog1109 trial for esophageal cancer